Filing Flows › Comparisons › SEPN vs LFCR
Septerna vs Lifecore Biomedical: SEPN and LFCR compared
Septerna is the larger company: $26.7M of revenue in its latest quarter (Q2 2026) against $25.3M for Lifecore Biomedical (Q1 FY27). Septerna is growing faster (225× against -19% a year earlier). Lifecore Biomedical is more profitable, with an operating margin of -3.5% against -62.9%.
Where the money goes: SEPN and LFCR
Septerna (SEPN) · Q2 2026
Septerna, Q2 2026: revenue $26.7M (225× year over year), operating margin -62.9%, net loss $13.0M, operating cash flow −$22.2M. The chart follows the revenue to costs, profit and cash.
Lifecore Biomedical (LFCR) · Q1 FY27
Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%, net loss $40.1M, operating cash flow $6.9M. The chart follows the revenue to costs, profit and cash.
| Septerna (SEPN) | Lifecore Biomedical (LFCR) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY27 |
| Revenue | $26.7M | $25.3M |
| Revenue growth, Y/Y | 225× | -19% |
| Operating margin | -62.9% | -3.5% |
| Net earnings | −$13.0M | −$40.1M |
| Net margin | -48.7% | -158.3% |
| Operating cash flow | −$22.2M | $6.9M |
| Free cash flow | — | $6.0M |
Where the revenue comes from
Lifecore Biomedical
- CDMO: $17.8M (70%)
- HA manufacturing: $7.5M (30%)
Questions
Which is bigger, Septerna or Lifecore Biomedical?
Septerna is the larger company: $26.7M of revenue in its latest quarter (Q2 2026) against $25.3M for Lifecore Biomedical (Q1 FY27).
Is Septerna or Lifecore Biomedical growing faster?
Septerna is growing faster (225× against -19% a year earlier).
Which is more profitable, Septerna or Lifecore Biomedical?
Lifecore Biomedical is more profitable, with an operating margin of -3.5% against -62.9%.
More: Septerna earnings · how Septerna makes money · Lifecore Biomedical earnings · how Lifecore Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 10, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.